Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $10.80
by Amy Steele · The Cerbat GemShares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) have been given an average rating of “Moderate Buy” by the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $10.80.
A number of research firms have commented on XERS. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th.
Get Our Latest Stock Report on Xeris Biopharma
Insiders Place Their Bets
In other Xeris Biopharma news, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $6.25, for a total value of $104,168.75. Following the transaction, the insider directly owned 1,226,507 shares in the company, valued at approximately $7,665,668.75. The trade was a 1.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James Aloysius Brady sold 10,834 shares of Xeris Biopharma stock in a transaction on Monday, March 30th. The shares were sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the transaction, the director owned 89,166 shares in the company, valued at approximately $493,979.64. This represents a 10.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 60,835 shares of company stock worth $388,194. 4.56% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Kestra Advisory Services LLC acquired a new position in shares of Xeris Biopharma during the fourth quarter worth about $25,000. AlphaQuest LLC acquired a new position in shares of Xeris Biopharma during the third quarter worth about $35,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after acquiring an additional 1,820 shares during the period. 42.75% of the stock is currently owned by institutional investors and hedge funds.
Xeris Biopharma Price Performance
Shares of XERS opened at $6.05 on Friday. Xeris Biopharma has a 1-year low of $4.16 and a 1-year high of $10.08. The stock has a market cap of $1.04 billion, a PE ratio of -604.40 and a beta of 0.77. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.57. The firm has a fifty day moving average price of $5.99 and a 200 day moving average price of $7.07.
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. As a group, sell-side analysts anticipate that Xeris Biopharma will post 0.12 EPS for the current year.
Xeris Biopharma Company Profile
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.